Single-center, Open-label, Randomized Study of Anemia Management Improvement in End Stage Renal Disease (ESRD) Patients With Secondary Hyperparathyroidism

Trial Profile

Single-center, Open-label, Randomized Study of Anemia Management Improvement in End Stage Renal Disease (ESRD) Patients With Secondary Hyperparathyroidism

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Cinacalcet (Primary) ; Paricalcitol (Primary) ; Calcium; Calcium acetate; Calcium acetate/magnesium carbonate; Lanthanum carbonate; Sevelamer; Vitamin D
  • Indications Hyperparathyroidism
  • Focus Therapeutic Use
  • Acronyms OPTIMAL
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Sep 2015 Planned End Date changed from 1 Oct 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.
    • 14 Sep 2015 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top